纤溶酶治疗结核性胸膜炎胸膜肥厚的疗效分析

摘要

Objective Clinical effect of plasmin in treatment of pleural thickening of tuberculosis pleurisy is to be studied.MethodsChoose 56 patients of pleural thickening of tuberculosis pleurisy who are treated in hospital from January 2012 to March 2014 and separate them into control group and study group at random; patients in control group are given urokinase treatment, while patients in study group are given plasmin treatment; then compare patients’ treatment effects between two groups.ResultsPatients’ treatment efficacy in study group is 71.4%, while patients’ treatment efficacy in control group is 92.9%, treatment efficacy in study group is much higher than that in control group, there is a treatment differential between two groups and such a differential has statistic value (P< 0.05). Conclusion Plasmin is of efficacy in treatment of pleural thickening of tuberculosis pleurisy; it is conducive to promoting absorption of pleural fluid and shrinking pleural thickening, thus, plasmin is a kind of safe medication in treatment of pleural thickening of tuberculosis pleurisy.%目的：对纤溶酶治疗结核性胸膜炎胸膜肥厚的临床效果进行分析研究。方法选取于2012年1月～2014年3月在我院接受治疗的56例结核性胸膜炎胸膜肥厚患者并随机分为两组，对照组患者给予尿激酶治疗，治疗组患者加用纤溶酶进行治疗，对两组患者的治疗效果进行比较。结果对照组患者的治疗总有效率为71.4%，治疗组患者的治疗总有效率为92.9%，则治疗组患者的临床效果显著优于对照组，差异显著，治疗有统计学意义（P<0.05）。结论纤溶酶治疗结核性胸膜炎胸膜肥厚的疗效十分显著，能够有效促进胸液吸收以及减少胸膜肥厚，是临床上治疗结核性胸膜炎胸膜肥厚的一种安全有效的药物。